Advertisement

Breast Cancer Research and Treatment

, Volume 109, Issue 1, pp 187–188 | Cite as

Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy

  • Gianluigi Ferretti
  • Paola Papaldo
Letter to the Editor
  • 54 Downloads

Keywords

Epirubicin Acute Myeloid Leukaemia Filgrastim Hazard Rate Ratio Median Cumulative Dose 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ferretti G, Papaldo P, Cognetti F, Dale DC, Rosenberg PS, Alter BP, Kaushansky K (2006) Lineage-specific hematopoietic growth factors. N Engl J Med 355(5):526–527PubMedCrossRefGoogle Scholar
  2. 2.
    Hershman D, Neugut AI, Jacobson JS, Wang J, Tsai W-Y, McBride R, Bennett CL, Grann VR (2007) Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99:196–205PubMedCrossRefGoogle Scholar
  3. 3.
    Touw P, Bontenbal M (2007) Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J Natl Cancer Inst 99(3):183–186PubMedCrossRefGoogle Scholar
  4. 4.
    Smith RE, Bryant J, DeCillis A, Anderson S (2003) National Surgical Adjuvant Breast and Bowel Project Experience. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience. J Clin Oncol 21:1195–1204PubMedCrossRefGoogle Scholar
  5. 5.
    Praga C, Bergh J, Bliss J, Bonneterre J, Cesana B, Coombes RC, Fargeot P, Folin A, Fumoleau P, Giuliani R, Kerbrat P, Hery M, Nilsson J, Onida F, Piccart M, Shepherd L, Therasse P, Wils J, Rogers D (2005) Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide. J Clin Oncol 23(18):4179–4191PubMedCrossRefGoogle Scholar
  6. 6.
    Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Bergh J (2007) Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 18:694–700 [Epub ahead of print]PubMedCrossRefGoogle Scholar
  7. 7.
    Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K (2003) Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada clinical trials group. J Clin Oncol 21:3066–3071PubMedCrossRefGoogle Scholar
  8. 8.
    Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431–1439PubMedCrossRefGoogle Scholar
  9. 9.
    Papaldo P, Lopez M, Cortesi E, Cammilluzzi E, Antimi M, Terzoli E, Lepidini G, Vici P, Barone C, Ferretti G, Di Cosimo S, Nistico C, Carlini P, Conti F, Di Lauro L, Botti C, Vitucci C, Fabi A, Giannarelli D, Marolla P (2003) The addition of either lonidamine or granulocyte colony-stimulating factor does not improve survival in early breast cancer patients treated with high-dose epirubicin and cyclophosphamide. J Clin Oncol 21(18):3462–3468PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  1. 1.Division of Medical Oncology ARegina Elena Cancer InstituteRomeItaly

Personalised recommendations